📸 Photos from SPIE Photonics West in San Francisco: the global hub for optics & photonics innovation. Great to see Patrick Ruane, COO of Re‑Vana Therapeutics, engaging with fellow business leaders from Northern Ireland and beyond.
Re-Vana Therapeutics will be in San Francisco (Jan 12–15) during #JPM2026. Our CEO Michael O'Rourke, COO Patrick Ruane, and CBO Hans Christinger look forward to connecting as we expand strategic collaborations in sustained-release solutions for biologics, peptides, and small & large molecules.
This month’s #EmployeeSpotlight features Hardik Shah, Junior Scientist at Re-Vana Therapeutics. From OcuLief® and EyeLief® to our Boehringer Ingelheim partnership, Hardik brings curiosity and collaboration to every project.
Re-Vana COO, Patrick Ruane, to presents at #PODD2025 on Oct 27 in Boston: "The Sustained Release of Biologics, Peptides, Large and Small Molecules with Novel Photo Crosslinked Biodegradable Technologies." #PODD2025
Our CEO Michael O’Rourke joined the Base to Base podcast to discuss Re-Vana’s $1B+ partnership with Boehringer Ingelheim and our vision for long-acting ocular therapies.
Listen here from minute 04:00 to 20:30: rss.com/podcasts/bas...
Re-Vana Therapeutics CEO Michael J. O’Rourke will present at Eyecelerator @ AAO 2025 on Oct 16 in Orlando, Florida in the Delivery Device Surgical session during the Presenting Company Showcases beginning at 1:15 p.m. #Eyecelerator #AAO2025
We're excited to share Re-Vana's feature by David Wild: “Boehringer Strengthens Partner Ecosystem To Drive Early Ophthalmology Innovation.”
“The real insight…is how they're rethinking the entire treatment paradigm, not just extending drug delivery.”
Read more: www.revanatx.com/boehringer-s...
We’re growing! Re-Vana Therapeutics is excited to welcome six new team members:
Hans Christinger – Chief Business Officer
Jim McIlroy – Vice President, Quality
JJ Hancock – Vice President, R&D
Daphne Doucet – Chief of Staff
Aaron Phillips – Formulation Scientist
Naomi Tully – Laboratory Scientist
Re-Vana is thrilled to welcome Hans Christinger as Chief Business Officer! With 30+ years of biotech leadership, from Roche & Abbott to founding GRIN & Modig, Hans brings vision, experience & passion to drive our next stage of growth.
Last week, our CEO, Michael J. O’Rourke, had the opportunity to present at two major ophthalmology conferences in Paris: the Ophthalmology Futures Forums Retina 2025 and the EURETINA Innovation Spotlight (EIS). #OFF2025 #EIS2025
Meet Charles Haughey, Laboratory Operations and Innovation Lead at Re-Vana Therapeutics and our latest #EmployeeSpotlight
Re-Vana is pleased to announce that our CEO, Michael O’Rourke, will present at Ophthalmology Futures Forums Retina 2025 (Panel 3: Neovascular AMD) and at the EURETINA Innovation Spotlight 2025 (Rapid Fire Panel Presentation and Discussion) on Wed, Sept 3 in Paris. #OFF2025 #EIS2025
Boehringer Ingelheim and Re-Vana Therapeutics enter $1B+ collaboration to develop long-acting ophthalmic therapies using Re-Vana's delivery platforms. www.globenewswire.com/news-release...
Re-Vana is pleased to announce that our CEO, Michael O'Rourke, will present at OIS Retina Innovation Summit on July 29 at 11 AM during the Spotlight on Drug Delivery. #OIS2025
Meet Aishwarya Khadanga, Laboratory Scientist at Re-Vana and our June #EmployeeSpotlight!
She’s helping drive innovation in sustained-release drug delivery for eye diseases—powered by curiosity, creativity, and a love of learning, in and out of the lab.
The Re-Vana team has a great time at the All-Ireland Round Robin Stage Gaelic Football match, Dublin vs Derry! A fun day of sport, team bonding & Irish culture. #TeamReVana
Re-Vana’s CEO, Michael J. O'Rourke to present at AECOS London, June 5–8, in the Innovations in Pharma session. #ophthalmology #innovation
www.linkedin.com/feed/update/...
Meet Gunjan Deshmukh, our May #EmployeeSpotlight! He leads biodegradable hydrogel development for sustained ocular drug delivery at Re-Vana Therapeutics.
www.linkedin.com/feed/update/...
Great insights and conversations at #Eyecelerator Park City! Thanks to all who connected with Re-Vana and to Michael J. O'Rourke for representing us on the S5 Drug Delivery Panel. Excited about the future of long-acting ophthalmic biologics. #ophthalmology www.linkedin.com/feed/update/...
Re-Vana’s CEO will join the Retina Unplugged panel at Retina World Congress, May 8–11 in Ft. Lauderdale. #ophthalmology #innovation
www.linkedin.com/feed/update/...
Re-Vana’s CEO & COO will attend Eyecelerator @ Park City May 2. Catch Michael J. O’Rourke on the S5 Drug Delivery Panel! #ophthalmology #eyecelerator www.linkedin.com/feed/update/...
Introducing Peter McKenna, our R&D Manager and April #EmployeeSpotlight! Learn what drives his passion for innovation at Re-Vana.
www.linkedin.com/feed/update/...
It was a pleasure to host Re-Vana’s BOD in Belfast! We showcased EyeLief® & OcuLief® and discussed the future of our sustained-release therapeutics.
Exciting times ahead! www.linkedin.com/feed/update/...
Excited to share the Rob & Jai Show – OIS Onsite Podcast! 🎙️ Re-Vana CEO Michael O'Rourke talks EyeLief® & OcuLief®, redefining biodegradable, sustained-release biologic implants. www.linkedin.com/feed/update/...
Meet Prerna Fule, our Junior Scientist! We caught up with her to talk about what inspires her and the passion that fuels her work #EmployeeSpotlight
Exciting news! Invest Northern Ireland is spotlighting Re-Vana Therapeutics as a leader in innovation! This aligns with our £215K R&D grant fuelling the development of OcuLief®, our photo crosslinked 6 months release biologic implant. Read the full post here: www.linkedin.com/feed/update/...
2025 is off to a great start at Re-Vana Therapeutics! We're advancing sustained-biologics for retina diseases, including a 6-month anti-VEGF implant. Plus, we’re celebrating new team members & well-earned promotions! 👏 Read the full post on our LinkedIn: www.linkedin.com/posts/re-van...